Abstract

INVESTIGATION OF ANTICANCER AND ANTIBACTERIAL ACTIVITY FROM ACACIA NILOTICA OF CRUDE AND PURE COMPOUND

Dr. Y. Thangam*, N. Suresh, K. Jaisankar and S. Kowsalya

Abstract

The antimicrobials in the therapeutics of infectious diseases were described over 2,500 years ago. At that time, they were regarded as the solution to all diseases caused by microorganisms. S. marcescens has been recognized as the cause of many hospital epidemics and a causative agent of hospitalized infection. It causes several diseases as a secondary infection such as urinary, respiratory, wound and septic arthritis, peritonitis and sinusitis. S. marcescens constitutively possesses chromosomally encoded, inducible Ampc β9 lactamases and may acquire plasmid- mediated extended-spectrum β-lactamases (ESBLs). S. marcescens was used in a number of classic bacterial transmission experiments, which led to improved understanding of the epidemiology of infection. From 1960 onwards, however, non-pigmented isolates of S. marcescens predominated over pigmented strains in the clinical setting and were increasingly implicated in healthcare associated infection. Limited research has been done, and many more pharmaceutical industries are interested in examining their potential as sources of novel medicinal compounds. Many bioactive compounds have been discovered from plants especially from Acacia nilotica, animals and microbes, such as natural products and secondary metabolites, which have been developed into drugs to treat diseases. Historically, natural products in the field of anti-cancer research has made significant achievements, over 60% of the clinical use of anti-cancer drugs originate from plants, marine organisms, microbes, and more than 3,000 species of plants can be used to treat cancer.

Keywords: S. marcescens, Acacia nilotica, animals and microbes.